Ministry of Justice
of the Azerbaijan Republic
 
 
 

Discordant rifampicin resistance results on MGIT960 and Xpert® MTB/RIF in the ТВ Control in Prisons Programme of Azerbaijan, Abstract

25.12.2015
E Gurbanova,1 КBlondal,2 F Mirzayev,3 R Tahirli,4 V Popova,4 R Mekhdiyev,1 A Ismayilov,5 A Altraja6
1
Main Medical Department of the Ministry of Justice, Baku, Azerbaijan;
2Department of Communicable Disease Prevention and Control, Reykjavik Health Care Services, Reykjavik, Iceland;
3Laboratories, Diagnostics & Drug Resistance Unit, World Health Organization, Geneva, Switzerland;
4Reference Laboratory, Specialized Treatment Institution for Detainees with Tuberculosis, Baku, Azerbaijan;
5Project HOPE, Dushanbe, Tajikistan;
6University of Tartu, Tartu, Estonia, e-mail: e.gurbanova@prisonhealth.az

Source: Abstract Book, 46th World International Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease

Background: The Main Medical Department of Azerbai­jan Ministry of Justice implements a comprehensive ТВ Control programme in the penitentiary system (PS). This programme practices active tuberculosis (ТВ) case finding among inmates and provides effective treatment for all identified cases of both susceptible and drug- resistant ТВin the Special Treatment Institution (STI). The STI also houses a modern reference laboratory that is quality-assured by the Supra-national Reference Labo­ratory in Borstel, Germany and performs all WHO- recommended diagnostics including Xpert MTB/RIF and culture with following drug-susceptibility testing (DST) on MGIT960. As soon as susceptibility result on R is available from either Xpert MTB/RIF or MGIT960, the patient starts adequate treatment with regimen adjust­ment after full DST is available. Since 2010, frozen cultures of all culture-positive samples processed in this laboratory are maintained.

Objectives: To assess the proportion of discordant R resistance results on Xpert MTB/RIF and MGIT960 among patients identified in Azerbaijan PS during 2011 - 2015.

Design and methods: All pulmonary ТВcases undergoing testing for ТВin STI were included into this retrospective study. ТВcases under treatment monitoring were excluded. Sputum samples from admitted patients were investigated both with Xpert MTB/RIF and MGIT960 culture and DST.To increase the number of strains evaluated, additional strains were revived from culture archive.
Results: Overall 532 strains were included, 286 consec­utive sputum samples from admitted patients and 246 frozen strains. Out of the 532 strains, 33 (6.2%) had discordant results, where 21 (3.9%) were R-resistant according to Xpert MTB/RIF, but R-sensitive according to MGIT960 and 12 (2.3%) were R-sensitive on Xpert MTB/RIF but R-resistant according to MGIT960 (Table 1). Both tests, however, were in a good agreement with each other (Cohen's kappa 0.825, P < 0.001). If MGIT results were taken as reference, then sensitivity, specific­ity, positive predictive value (PPV), negative predictive value (NPV) and test accuracy of Xpert MTB/RIF were 90.8%, 95.2%, 84.9%, 97.2% and 94.2% respectively. Table 1. Rifampicin susceptibility results by Xpert МТВ/ RIF and MGIT960. Xpert MTB/RIF Sensitive Resistant Total MGIT 960 Sensitive 393 21 414 Resistant 12 106 118 Total 405 127 532

Conclusions: Despite the 6.2% discordance between the methods, the results by Xpert MTB/RIF had acceptable sensitivity, specificity, PPV, NPV and accuracy and were in a good agreement with those obtained with MGIT960. Further research and sequencing will be necessary to better understand the genetic profile of strains that exhibit discordance in Rif susceptibility results between these two diagnostic ttechniques.97.2% and 94.2% respectively.